The article reports that Merck's acquisition of biotech firm Sirna in October 2006 indicates the commercial potential of RNA interference (RNAi) gene-slicing technology. Sirna, which emerged in 2003 from the former Ribozyme Pharmaceuticals, was the highest profile U.S.-based RNAi biotech company along with Alnylam.